AT Bancorp’s BioMarin Pharmaceuticals BMRN Stock Holding History

AT Bancorp’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-7,140	Closed	-$578K	–	228
2018 Q1	$578K	Buy	+7,140	New	+$613K	0.06%	149

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

AT Bancorp's BMRN Position: Q2 2018 in Review

AT Bancorp sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 7,140 shares — an estimated $578K sold.

AT Bancorp first reported a position in BMRN in Q1 2018 and held it in 1 quarter. The position peaked at $578K in Q1 2018. 448 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

AT Bancorp reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
AT Bancorp sold 7,140 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $578K.
AT Bancorp first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 1 quarter.
AT Bancorp's BioMarin Pharmaceuticals position peaked at $578K in Q1 2018.
448 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on AT Bancorp's 13F filing for Q2 2018, filed 8 Aug 2018.